Show simple item record

dc.creatorTao, Ran
dc.creatorWang, Zhong-Feng
dc.creatorQiu, Wei
dc.creatorHe, Yu-Fang
dc.creatorYan, Wei-Qun
dc.creatorSun, Wen-Yi
dc.creatorLi, Hai-Jun
dc.date.accessioned2021-01-22T21:36:57Z
dc.date.available2021-01-22T21:36:57Z
dc.date.issued2017-06
dc.identifier.issn1792-0981
dc.identifier.issn1792-1015
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4894
dc.identifier.otherEU5NW (isidoc)
dc.identifier.other28588665 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4912
dc.description.abstractThe fifth most common cancer worldwide is hepatocellular carcinoma (HCC), which has an annual mortality rate of ~800,000. Although surgical procedures for HCC, such as hepatic resection and liver transplantation, have progressed and the outcomes of patients have improved, HCC is still characterized by frequent recurrence, even after liver transplantation. In the present study the expression of the protein coding gene, S100 calcium binding protein A3 (S100A3), was observed in 62 HCC tissues and tumor-surrounding tissues. The present study indicated that S100A3 activation was involved in tumorigenesis and tumor aggressiveness. The protein and mRNA expression levels of S100A3 in the human HCC cell line (HepG2) were investigated using western blotting and reverse transcription-quantitative polymerase chain reaction analysis, respectively. The function of sodium cantharidinate in inducing HCC cell apoptosis was also investigated. Sodium cantharidinate inhibited the protein and gene expression of S100A3 in HepG2 cells in vitro. These data suggested that S100A3 has an important role in human HCC. The present study indicates that the functional properties of sodium cantharidinate are promising for the development of a novel drug that may control the expression of S100A3 and improve the treatment of human HCC in the near future.
dc.format.extent2812-2818
dc.language.isoen
dc.relation.haspartEXPERIMENTAL AND THERAPEUTIC MEDICINE
dc.relation.isreferencedbySpandidos Publications
dc.rightsCC BY-NC-ND
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectS100 calcium binding protein A3
dc.subjecthepatocellular carcinoma
dc.subjectsodium cantharidinate
dc.titleRole of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.3892/etm.2017.4294
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidTao, Rongjia|0000-0001-5058-4401
dc.date.updated2021-01-22T21:36:54Z
refterms.dateFOA2021-01-22T21:36:58Z


Files in this item

Thumbnail
Name:
Role of S100A3 in human hepato ...
Size:
963.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-ND
Except where otherwise noted, this item's license is described as CC BY-NC-ND